Celiprolol

Celiprolol

Clinical data
ATC code	C07AB08 (WHO)
Identifiers
IUPAC name N'-(3-Acetyl-4-(3-((1,1-dimethylethyl)amino) - 2-hydroxypropoxy)phenyl)-N,N-diethylurea
CAS Number	56980-93-9
PubChem CID	2663
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}
Chemical and physical data
Formula	C20H33N3O4
Molar mass	379.49 g/mol

WikiDoc Resources for Celiprolol
Articles
Most recent articles on Celiprolol Most cited articles on Celiprolol Review articles on Celiprolol Articles on Celiprolol in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Celiprolol Images of Celiprolol Photos of Celiprolol Podcasts & MP3s on Celiprolol Videos on Celiprolol
Evidence Based Medicine
Cochrane Collaboration on Celiprolol Bandolier on Celiprolol TRIP on Celiprolol
Clinical Trials
Ongoing Trials on Celiprolol at Clinical Trials.gov Trial results on Celiprolol Clinical Trials on Celiprolol at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Celiprolol NICE Guidance on Celiprolol NHS PRODIGY Guidance FDA on Celiprolol CDC on Celiprolol
Books
Books on Celiprolol
News
Celiprolol in the news Be alerted to news on Celiprolol News trends on Celiprolol
Commentary
Blogs on Celiprolol
Definitions
Definitions of Celiprolol
Patient Resources / Community
Patient resources on Celiprolol Discussion groups on Celiprolol Patient Handouts on Celiprolol Directions to Hospitals Treating Celiprolol Risk calculators and risk factors for Celiprolol
Healthcare Provider Resources
Symptoms of Celiprolol Causes & Risk Factors for Celiprolol Diagnostic studies for Celiprolol Treatment of Celiprolol
Continuing Medical Education (CME)
CME Programs on Celiprolol
International
Celiprolol en Espanol Celiprolol en Francais
Business
Celiprolol in the Marketplace Patents on Celiprolol
Experimental / Informatics
List of terms related to Celiprolol

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Celiprolol (brand names Cardem, Selectol, Celipres, Celipro, Celol, Cordiax, Dilanorm) is a medication in the class of beta blockers, used in the treatment of high blood pressure. It has a unique pharmacology: it is a selective β1 receptor antagonist, but a β2 receptor partial agonist. It is also a weak α2 receptor antagonist.

A recent clinical trial has suggested a use for this medication in the prevention of vascular complications of a rare inherited disease called vascular Ehlers–Danlos syndrome. This study demonstrated decreased incidence of arterial rupture or dissection (a specific type of arterial rupture in which the layers of the vessel separate prior to complete failure of the artery wall).

External Links

• Selectol Summary of Product Characteristics (from the IPHA Medicines Compendium)
• Celiprolol data sheet for New Zealand